Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
Jan 5,2024
Empagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used to lower blood sugar in adults with type 2 diabetes. Empagliflozin also exerts cardioprotective effects independent from glucose control. Empagliflozin did not alter baseline cardiac normal conduction activity. However, empagliflozin eliminated myocardial vulnerability to sudden cardiac death (from 69.2% mortality rate in the control group to 0% in the empagliflozin group) and reduced the susceptibility to reperfusion-induced arrhythmias post I/R injury. Empagliflozin increased phosphorylation of cardiac ERK1/2 after reperfusion injury. Furthermore, inhibition of ERK1/2 using U0126 abolished the anti-arrhythmic action of empagliflozin and ERK1/2 phosphorylation.
Pretreatment with empagliflozin protects the heart from subsequent severe lethal ventricular arrhythmia induced by myocardial ischemia and reperfusion injury. These protective benefits may occur as a consequence of activation of the ERK1/2-dependent cell-survival signaling pathway in a glucose-independent manner.
A potential anticancer drug
Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a highly effective and well-tolerated antidiabetic drug. In addition to hypoglycemic effects, empagliflozin has many other effects, such as being hypotensive and cardioprotective. It also has anti-inflammatory and antioxidative stress effects in diabetic nephropathy. Several studies have shown that empagliflozin has anticancer effects. SGLT2 is expressed in a variety of cancer cell lines. The SGLT2 inhibitor empagliflozin has significant inhibitory effects on certain types of tumor cells, such as inhibition of proliferation, migration and induction of apoptosis. In conclusion, empagliflozin has promising applications in cancer therapy as a drug for the treatment of diabetes and heart failure.
References:
[1] ZHAOYANG HU. Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death.[J]. Cardiovascular Diabetology, 2021. DOI:10.1186/s12933-021-01392-6.
[2] WENWEN WU. Empagliflozin: a potential anticancer drug.[J]. Discover. Oncology, 2023. DOI:10.1007/s12672-023-00719-x.
- Related articles
- Related Qustion
- Which is better in the treatment of heart failure, Empagliflozin or Dapagliflozin? Aug 13, 2024
Empagliflozin is a drug approved for the treatment of type 2 diabetes in adults.
- An analytical study of empagliflozin in the risk of gout Dec 13, 2023
Empagliflozin is an FDA-approved antidiabetic drug in the sodium-glucose cotransporter protein (SGLT-2) class of diabetes medications that is used in adults with type 2 diabetes, and in patients with type 2 diabetes with heart and blood ves
- Pharmacological effects of empagliflozin Apr 20, 2022
Empagliflozin is a type 2 sodium glucose cotransporter (SGLT-2, sodium-dependent glucose cotransporter2) inhibitor jointly developed by Boehringer Ingelheim and Eli Lilly.
2,5-Furandicarboxylic acid can replace petroleum-based terephthalic acid to produce biobased plastic polyethylene furan dicarboxylate (PEF) due to the similarity in its functional group with terephthalic acid.....
Jan 5,2024Organic ChemistryThe sharing of electrons between O and H is unequal, with the electrons more strongly drawn towards O. This results in an overall polar molecule.....
Jan 5,2024Organic ChemistryEmpagliflozin
864070-44-0You may like
- Empagliflozin
- $220.00 / 1Kg/Bag
- 2024-11-04
- CAS:864070-44-0
- Min. Order: 1Kg/Bag
- Purity: 99% up, High Density
- Supply Ability: 20 tons
- Empagliflozin
- $39.00 / 5mg
- 2024-11-04
- CAS:864070-44-0
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
- Empagliflozin
- $1.00 / 1kg
- 2024-11-04
- CAS:864070-44-0
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1 ton